PE20140716A1 - Compuestos y su usos - Google Patents

Compuestos y su usos

Info

Publication number
PE20140716A1
PE20140716A1 PE2013001276A PE2013001276A PE20140716A1 PE 20140716 A1 PE20140716 A1 PE 20140716A1 PE 2013001276 A PE2013001276 A PE 2013001276A PE 2013001276 A PE2013001276 A PE 2013001276A PE 20140716 A1 PE20140716 A1 PE 20140716A1
Authority
PE
Peru
Prior art keywords
methyl
trioxo
thia
hept
triazol
Prior art date
Application number
PE2013001276A
Other languages
English (en)
Inventor
Palanisamy Senthilkumar Udayampalayam
Maneesh Paul-Satyaseela
Shridhar Narayanan
Gopalan Balasubramanian
Aravind Appu
Senthilnathan Manickam
Hariharan Periasamy
Original Assignee
Allecra Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45757037&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140716(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allecra Therapeutics Gmbh filed Critical Allecra Therapeutics Gmbh
Publication of PE20140716A1 publication Critical patent/PE20140716A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/87—Compounds being unsubstituted in position 3 or with substituents other than only two methyl radicals attached in position 3, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/88—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/883—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with a substituted hydrocarbon radical attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I), DONDE HET REPRESENTA UN ANILLO HETEROCICLICO DE TRES A SIETE MIEMBROS; R1 ES UN ANION CARBOXILATO o -COOR4; R4 ES HIDROGENO, METOXIBENCILO, PIVOXILO, ENTRE OTROS; R2 Y R3 REPRESENTAN INDEPENDIENTEMENTE HIDROGENO, HALOGENO, AMINO, ENTRE OTROS, R REPRESENTA GRUPO C1-C6ALQUILO, C2-C6ALQUENILO, C6-C10ARILO, ENTRE OTROS.SON COMPUESTOS PREFERIDOS 1-{[(2S, 3S,5R)-2-CARBOXI-3-METIL-4,4,7-TRIOXO-4-TIA-1-AZABICICLO[3.2.0]HEPT-3-IL]METIL}-3-METIL-1H-1,2,3-TRIAZOL-3-IO; 1-{[(2S, 3S,5R)-2-CARBOXI-3-METIL-4,4,7-TRIOXO-4-TIA-1-AZABICICLO[3.2.0]HEPT-3-IL]METIL}-3-ETIL-1H-1,2,3-TRIAZOL-3-IO, ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN LA INHIBICION DE BETA-LACTAMASAS.
PE2013001276A 2010-11-25 2011-11-25 Compuestos y su usos PE20140716A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3555CH2010 2010-11-25
IN3096CH2011 2011-09-09

Publications (1)

Publication Number Publication Date
PE20140716A1 true PE20140716A1 (es) 2014-07-12

Family

ID=45757037

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001276A PE20140716A1 (es) 2010-11-25 2011-11-25 Compuestos y su usos

Country Status (28)

Country Link
US (1) US10201532B2 (es)
EP (1) EP2642992B1 (es)
JP (1) JP5961177B2 (es)
KR (1) KR101933084B1 (es)
CN (2) CN107260729B (es)
AP (1) AP2013006947A0 (es)
AU (1) AU2011333305B2 (es)
BR (1) BR112013012735B1 (es)
CA (1) CA2818100C (es)
CL (1) CL2013001482A1 (es)
CO (1) CO6781486A2 (es)
CR (1) CR20130306A (es)
DK (1) DK2642992T3 (es)
EA (1) EA030662B1 (es)
EC (1) ECSP13012716A (es)
ES (1) ES2859639T3 (es)
HU (1) HUE053623T2 (es)
IL (1) IL226538A (es)
MA (1) MA34760B1 (es)
MX (1) MX353447B (es)
MY (1) MY170435A (es)
NZ (1) NZ610247A (es)
PE (1) PE20140716A1 (es)
SG (1) SG190877A1 (es)
SV (1) SV2013004451A (es)
UA (1) UA115966C2 (es)
WO (1) WO2012070071A1 (es)
ZA (1) ZA201303773B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2993900B1 (fr) * 2012-07-27 2016-03-25 Biomerieux Sa Procede de detection de bacteries productrices de carbapenemases de type oxa-48
TW201922795A (zh) * 2012-09-10 2019-06-16 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
US20140128364A1 (en) * 2012-11-05 2014-05-08 Rempex Pharmaceuticals Therapeutic uses of tigemonam and carumonam
GB201319776D0 (en) * 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
GB201408649D0 (en) * 2014-05-15 2014-07-02 Allecra Therapeutics Sas Method
JP2016010399A (ja) * 2014-06-03 2016-01-21 日水製薬株式会社 カルバペネマーゼ産生耐性菌検出用組成物
FR3024465B1 (fr) * 2014-07-30 2018-03-23 Biomerieux Caracterisation de micro-organismes par maldi-tof
EP3372587A1 (en) * 2017-03-09 2018-09-12 Centre National de la Recherche Scientifique (CNRS) 3-imidazolines as carbapenemases inhibitors
SI25892A (sl) * 2019-09-05 2021-03-31 Gorenje Gospodinjski Aparati, D.O.O. Pralni stroj, ki se polni s sprednje strani, z električnim svetlobnim telesom
WO2021048613A2 (en) * 2019-09-11 2021-03-18 Tennor Therapeutics Limited Penam derivatives for treating bacterial infections
CN110840897B (zh) * 2019-11-28 2023-08-08 河北旺发生物科技有限公司 金属β-内酰胺酶抑制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59118790A (ja) * 1982-12-24 1984-07-09 Taiho Yakuhin Kogyo Kk ペニシリン誘導体
US4562073A (en) 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
JPS60215688A (ja) * 1984-04-09 1985-10-29 Taiho Yakuhin Kogyo Kk ペニシリン誘導体
US4891369A (en) 1986-12-03 1990-01-02 Taiho Pharmaceutical Company, Limited 2β-Substituted-methylpenicillanic acid derivatives, and salts and esters thereof
JP2599595B2 (ja) * 1987-06-26 1997-04-09 大鵬薬品工業株式会社 ２β−置換メチルペニシラン酸誘導体、その塩及びエステル
JP2648750B2 (ja) * 1988-03-02 1997-09-03 大塚化学株式会社 β−ラクタム誘導体の製造方法
DK1468697T3 (da) 2003-04-14 2008-04-14 Wyeth Corp Sammensætninger indeholdende piperacillin og tazobactam, der er anvendelige til injektion
JP2008516967A (ja) 2004-10-14 2008-05-22 ワイス 乳酸ナトリウム希釈液中にピペラシリン、タゾバクタムおよびアミノカルボン酸を含む組成物
WO2008010048A2 (en) * 2006-07-12 2008-01-24 Orchid Chemicals & Pharmaceuticals Limited Novel 2-substituted methyl penam derivatives
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments

Also Published As

Publication number Publication date
DK2642992T3 (da) 2021-03-01
WO2012070071A1 (en) 2012-05-31
ECSP13012716A (es) 2013-08-30
EA201300617A1 (ru) 2014-03-31
AP2013006947A0 (en) 2013-06-30
EP2642992A1 (en) 2013-10-02
MA34760B1 (fr) 2013-12-03
SV2013004451A (es) 2017-12-01
AU2011333305A1 (en) 2013-07-11
WO2012070071A9 (en) 2012-08-16
CN103347515B (zh) 2017-06-06
CN107260729B (zh) 2020-03-31
BR112013012735B1 (pt) 2021-11-23
UA115966C2 (uk) 2018-01-25
MX2013005907A (es) 2013-12-06
ZA201303773B (en) 2014-11-26
HUE053623T2 (hu) 2021-07-28
CO6781486A2 (es) 2013-10-31
US10201532B2 (en) 2019-02-12
SG190877A1 (en) 2013-07-31
IL226538A (en) 2017-07-31
JP2014504279A (ja) 2014-02-20
CN107260729A (zh) 2017-10-20
MX353447B (es) 2018-01-11
NZ610247A (en) 2014-09-26
CR20130306A (es) 2013-09-18
JP5961177B2 (ja) 2016-08-02
AU2011333305B2 (en) 2017-06-22
US20140057888A1 (en) 2014-02-27
MY170435A (en) 2019-07-31
EA030662B1 (ru) 2018-09-28
CL2013001482A1 (es) 2014-04-04
ES2859639T3 (es) 2021-10-04
KR20140052927A (ko) 2014-05-07
BR112013012735A2 (pt) 2017-11-07
CN103347515A (zh) 2013-10-09
CA2818100C (en) 2019-07-09
BR112013012735A8 (pt) 2021-10-26
EP2642992B1 (en) 2020-11-25
CA2818100A1 (en) 2012-05-31
KR101933084B1 (ko) 2018-12-28

Similar Documents

Publication Publication Date Title
PE20140716A1 (es) Compuestos y su usos
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
ECSP12012292A (es) Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos
PE20140011A1 (es) Compuestos y composiciones novedosos para la inhibicion de nampt
EA201700230A1 (ru) Определенные аминопиридины, композиции на их основе и способы их применения
PE20130155A1 (es) Derivados de ariletinilo
PE20150041A1 (es) Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
CL2011002825A1 (es) Compuestos derivados de bencimidazol heteroarilo sustituido; composición farmacéutica que los comprende; y su uso en el tratamiento de la hepatitis c.
ATE459622T1 (de) Tropanverbindungen
TW200738655A (en) Novel bicyclic sulfonamide derivatives
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
ECSP056016A (es) Nuevos derivados de 2-piridinacarboxamida
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
PE20110368A1 (es) Moduladores de mif
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
PE20081882A1 (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
PE20110843A1 (es) Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica
PE20121438A1 (es) Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a
UY29486A1 (es) Compuestos utiles en terapia
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
DE602007012875D1 (de) Benzimidazole und ihre verwendung zur behandlung von diabetes
AR062258A1 (es) Compuestos heterociclicos condensados de tieno-pirrol, composiciones farmaceuticas que los contienen y usos para el tratamiento de infecciones por hcv

Legal Events

Date Code Title Description
FD Application declared void or lapsed